Advertisement
U.S. Markets open in 5 hrs 56 mins

Karolinska Development AB (publ) (KDEV.ST)

Stockholm - Stockholm Real Time Price. Currency in SEK
1.0140-0.0200 (-1.93%)
As of 09:25AM CET. Market open.
Full screen
Previous Close1.0340
Open1.0380
Bid1.0100 x 0
Ask1.0240 x 0
Day's Range1.0000 - 1.0380
52 Week Range0.9500 - 1.9480
Volume37,366
Avg. Volume292,874
Market Cap273.611M
Beta (5Y Monthly)0.19
PE Ratio (TTM)N/A
EPS (TTM)-0.1100
Earnings DateFeb 14, 2025
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.40
  • GlobeNewswire

    Karolinska Development's portfolio company Modus Therapeutics secures bridge financing

    STOCKHOLM, SWEDEN November 19, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Modus Therapeutics has secured access to bridge financing of up to SEK 5 million from Karolinska Development, the company’s largest shareholder. The funding enables Modus to initiate the recently approved phase 2a study in chronic kidney disease. ”Modus Therapeutics research is gaining momentum and with this funding they now have the opportunity to maintain a good pa

  • GlobeNewswire

    Karolinska Development’s portfolio company Umecrine Cognition presents positive interim data from Phase 1b/2a clinical study

    STOCKHOLM, SWEDEN – November 18, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition will present data from a recent interim analysis from an ongoing Phase 1b/2a clinical study of golexanolone in patients with Primary Biliary Cholangitis. The preliminary results show that golexanolone was well-tolerated and achieved drug exposure levels that correlate to clinical treatment doses. The results will be presented at the Late Breaking